EyePoint (EYPT) Total Current Liabilities (2011 - 2026)
EyePoint (EYPT) posted Total Current Liabilities of $37.5 million for Q1 2026, up 1.18% sequentially from $37.0 million in Q4 2025, and down 10.12% YoY from $41.7 million in Q1 2025.
Analysis
EyePoint (EYPT) Total Current Liabilities (2011 - 2026) Analysis & Trends
EyePoint has reported Total Current Liabilities for 16 years, with the latest figure at $37.5 million in Q1 2026.
- Quarterly Total Current Liabilities fell 10.12% year-over-year to $37.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.5 million (down 10.12% YoY) and the FY2025 annual result came in at $37.0 million, down 24.51% from the prior year.
- Total Current Liabilities climbed to $37.5 million in Q1 2026 per EYPT's latest filing, from $37.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $68.9 million in Q2 2023 and troughed at $27.2 million in Q1 2023.
- A 5-year average of $44.7 million and a median of $37.5 million in 2026 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 137.86% in 2022, then slumped 46.58% in 2025.
- Over 5 years, Total Current Liabilities stood at $34.5 million in 2022, then jumped by 83.17% to $63.3 million in 2023, then retreated by 22.47% to $49.0 million in 2024, then decreased by 24.51% to $37.0 million in 2025, then gained by 1.18% to $37.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $37.5 million, $37.0 million, and $30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 41.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.94 Mn |
| Mar 31, 2026 | 37.46 Mn |
| Dec 31, 2025 | 37.02 Mn |
| Sep 30, 2025 | 30.09 Mn |
| Jun 30, 2025 | 33.18 Mn |
| Mar 31, 2025 | 41.68 Mn |
| Dec 31, 2024 | 49.05 Mn |
| Sep 30, 2024 | 48.79 Mn |
| Jun 30, 2024 | 62.10 Mn |
| Mar 31, 2024 | 62.58 Mn |
| Dec 31, 2023 | 63.26 Mn |
| Sep 30, 2023 | 63.90 Mn |
| Jun 30, 2023 | 68.92 Mn |
| Mar 31, 2023 | 27.24 Mn |
| Dec 31, 2022 | 34.54 Mn |
| Sep 30, 2022 | 34.26 Mn |
| Jun 30, 2022 | 33.39 Mn |
| Mar 31, 2022 | 31.97 Mn |
| Dec 31, 2021 | 23.66 Mn |
| Sep 30, 2021 | 19.93 Mn |